中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2010年
5期
362-363
,共2页
周玉麟%王学才%吴寅涛%谈永飞%赵彦平%汤俊明%潘建强
週玉麟%王學纔%吳寅濤%談永飛%趙彥平%湯俊明%潘建彊
주옥린%왕학재%오인도%담영비%조언평%탕준명%반건강
阿德福韦酯%肝炎,乙型,慢性%肝炎病毒,乙型%T淋巴细胞,细胞毒性
阿德福韋酯%肝炎,乙型,慢性%肝炎病毒,乙型%T淋巴細胞,細胞毒性
아덕복위지%간염,을형,만성%간염병독,을형%T림파세포,세포독성
Adefovir dipivoxil%Hepatitis B,Chronic%Hepatitis B viras%T-Lymphocytes,cytotoxic
目的 探讨阿德福韦酯对慢性乙型肝炎(CHB)患者HBV特异性CTL的影响.方法 对HBV DNA阳性(HBV DNA≥1×104拷贝/ml)、ALT＞2×正常值上限(ULN)、人白细胞抗原(HLA)-A2阳性的CHB患者用阿德福韦酯(正大天睛药业公司生产)10 mg,口服,每日1次,3个月.用实时荧光定量PCR检测HBV DNA,流式细胞术检测HBV特异性CTL.结果 阿德福韦酯治疗3个月后,HBV特异性CTL(0.52±0.11)%高于治疗前(0.34±0.14)%,t=6.78 P＜0.01,HBV DNA阴转(＜1×103拷贝/ml)28例(62.22%).17例未阴转的患者,HBV DNA水平治疗后3个月[(4.18±0.4)log10拷贝/ml]低于治疗前[(6.23±0.73)log10拷贝/ml]t=9.99,P＜0.01.结论 阿德福韦酯能提高CHB患者的HBV特异性细胞免疫功能.
目的 探討阿德福韋酯對慢性乙型肝炎(CHB)患者HBV特異性CTL的影響.方法 對HBV DNA暘性(HBV DNA≥1×104拷貝/ml)、ALT＞2×正常值上限(ULN)、人白細胞抗原(HLA)-A2暘性的CHB患者用阿德福韋酯(正大天睛藥業公司生產)10 mg,口服,每日1次,3箇月.用實時熒光定量PCR檢測HBV DNA,流式細胞術檢測HBV特異性CTL.結果 阿德福韋酯治療3箇月後,HBV特異性CTL(0.52±0.11)%高于治療前(0.34±0.14)%,t=6.78 P＜0.01,HBV DNA陰轉(＜1×103拷貝/ml)28例(62.22%).17例未陰轉的患者,HBV DNA水平治療後3箇月[(4.18±0.4)log10拷貝/ml]低于治療前[(6.23±0.73)log10拷貝/ml]t=9.99,P＜0.01.結論 阿德福韋酯能提高CHB患者的HBV特異性細胞免疫功能.
목적 탐토아덕복위지대만성을형간염(CHB)환자HBV특이성CTL적영향.방법 대HBV DNA양성(HBV DNA≥1×104고패/ml)、ALT＞2×정상치상한(ULN)、인백세포항원(HLA)-A2양성적CHB환자용아덕복위지(정대천정약업공사생산)10 mg,구복,매일1차,3개월.용실시형광정량PCR검측HBV DNA,류식세포술검측HBV특이성CTL.결과 아덕복위지치료3개월후,HBV특이성CTL(0.52±0.11)%고우치료전(0.34±0.14)%,t=6.78 P＜0.01,HBV DNA음전(＜1×103고패/ml)28례(62.22%).17례미음전적환자,HBV DNA수평치료후3개월[(4.18±0.4)log10고패/ml]저우치료전[(6.23±0.73)log10고패/ml]t=9.99,P＜0.01.결론 아덕복위지능제고CHB환자적HBV특이성세포면역공능.
Objective To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB). Methods 10 mg adefovir dipivoxil (Zhengda Tianjing Pharmaceutical Company) was used for CHB patients with positive HBV DNA (HBV DNA ≥ 1 × 104 copies/ml) ,ALT ＞ 2 × upper limit of normal value (ULN) and positive human leucocyte antigen (HLA)-A2,orally,once a day for 3 months. Real time fluorescent quantitative PCR was used to determine HBV DNA and flowcytometer was used to determine HBV specific CTL. Results After treatment with adefovir dipivoxil for 3 months, HBV specific CTL (0. 52 ± 0. 11 )% was higher than that before treatment(0. 34 ± 0. 14 )% , t =6.78 P ＜0. 01, HBV DNA of 28 cases turned to negative ( ＜ 1 × 103copies/ml) (62. 22% ). HBV DNA of 17 cases failed to turn negative 3 months after treatment,but their HBV DNA level was lower [(4. 18 ±0.4)log 10 copies/ml] than that before treatment [(6. 23 ± 0. 73 ) log 10 copies/ml], t = 9.99, P ＜ 0.01.Conclusion adefovir dipivoxil can improve HBV specific cellular immunity in patients CHB.
